Senetek and Beiersdorf, Manufacturer of World's Biggest Skin Care Brand, Announce Collaboration
Wednesday June 25, 8:01 am ET
NAPA, Calif. and HAMBURG, Germany, June 25 /PRNewswire-FirstCall/ -- Beiersdorf
AG, Hamburg, Germany, and Senetek PLC (Nasdaq: SNTK - News),
www.senetekplc.com , Napa, California, today announced that they have entered into a
research collaboration agreement in which Beiersdorf will undertake laboratory and in
vivo evaluations of various compounds for which Senetek has rights.
After the conclusion of each evaluation, Beiersdorf may enter into licenses for the use
of the compound in specific markets worldwide. Senetek will own and have the right to
practice and license all compounds resulting from this collaboration outside of the
markets and fields of use that may be licensed to Beiersdorf.
Beiersdorf develops, produces and markets products worldwide for women's and men's
skin care and personal care under a number of global brand names, including Nivea®,
the world's biggest skin and personal care brand. Beiersdorf's research and
development programs for this product category focus on further development of its
successful technologies for protecting the skin from photo damage and treating the
skin aging process.
Senetek, a healthcare technologies company focused on developing and co-marketing
products for the anti-aging markets in key skin care/dermatologicals and sexual
dysfunction categories, currently licenses a number of major pharmaceutical and skin
care manufacturers and distributors to use Senetek's patented Kinetin compound in
dermatological and skin care products with proven anti-aging activity, sold worldwide.
Dr. Klaus-Peter Wittern, Corporate Vice-President of Research & Development at
Beiersdorf, described the Collaboration Agreement with Senetek as "a remarkable
opportunity for Beiersdorf to further enhance its wide range of innovative high-quality
skin care formulations. Beiersdorf has a long tradition of successfully working with
excellent scientific partners, who help us multiply our strong internal R&D force,
ultimately generating skin care products with proven and perceivable advantages for
our consumers."
Frank Massino, Chairman and CEO of Senetek, stated that "the signing of this
Research and Development agreement with Beiersdorf, one of the major skin care
companies in the world, in combination with the recently established relationship with
the Institute of Experimental Botany in the Czech Republic, validates Senetek's strategy
to become a global player based on its core technologies and competencies. We are
now properly positioned in Europe with the additions of Andreas Tobler, Chief
Operating Officer and Managing Director, Europe and Dr. Brian Clark, Chief Scientist,
both of whom were most instrumental in making this important relationship possible."
Visit Senetek PLC's web site: senetekplc.com
Senetek PLC Investor Relations Contact:
1-707-226-3900 ext. 102
E-Mail: Pknopick@eandecommunications.com
Source: Senetek PLC |
